Total glycans from the cell layer and the culture medium of human vascular smooth muscle cells (VSMC) that had been cultivated in the presence of plateletderived growth factor (PDGF) were isolated and purified by gel filtration after Pronase and DNase digestion and alkaliborohydride treatment. Measurements of the content of neutral hexoses and uronic acids revealed that PDGF stimulates total glycan synthesis by proliferating VSMC in a linear fashion from 24 h to 72 h of incubation. In contrast, total glycan synthesis by human fibroblasts, epithelial cells, or endothelial cells was not affected by PDGF, indicating celltype specificity. Chemical, biochemical, and enzymological characterization of the total glycans synthesized by VSMC showed that PDGF stimulates the secretion of a 340-kDa glycan molecule in a time-dependent manner from 24 h to 72 h. This molecule is highly acidic, shares a common structure with hyaluronic acid, and exhibits a potent antiproliferative activity on VSMC. These results suggest that VSMC in response to PDGF are capable of controlling their own growth and migration by the synthesis of a specific form of hyaluronic acid with antiproliferative potency, which may be involved in the regulation of the local inflammatory responses associated with atherosclerosis.
The intimal lesions of advanced atherosclerosis are characterized by an increased mass of vascular smooth muscle cells (VSMC), which implies an increment in proliferation and/or migration of VSMC. This involves a transition of VSMC from a quiescent/differentiated to a proliferating/dedifferentiated phenotype. The mechanisms underlying the migration of VSMC into the intima and their modulation into a proliferative phenotype in atherosclerosis have been reviewed by Ross (1) .
Among several growth factors, platelet-derived growth factor (PDGF) has been shown to be essentially involved in VSMC proliferation (2, 3) and migration (4, 5) . PDGF is generally not expressed in the normal artery, whereas it is upregulated in lesions of atherosclerosis. The lesions at all stages of development from both humans and nonhuman primates contain the PDGF-BB isoform. The capacity to respond to this mitogen is associated with increased numbers of PDGF-receptors on adjacent intimal VSMC in the same lesions (6, 7) .
Increasing evidence suggests that the storage and activity of PDGF is influenced by extracellular matrix molecules. For example, heparin, a product of endothelium and smooth muscle, can bind and inactivate PDGF and thus inhibit the PDGF-induced migration and proliferation of VSMC (8) . Furthermore, it has been shown that arterial proteoglycans from human atherosclerotic lesions contain a small but significant amount of heparin-like (heparan sulfate) glycosaminoglycans (GAGs) (9) , which are also produced in vitro by vascular endothelial cells (10, 11) and VSMC (12) . The above evidence indicates that GAGs are implicated in the regulation of the inflammatory responses involved in atherosclerosis. However, there is no information related to the precise characterization of the total glycan molecules that are produced by VSMC during the development of atherosclerotic lesions.
METHODS
Cell Cultures. Primary human lung VSMC and fibroblasts were established from sterile lung biopsies and cultivated in RPMI 1640 medium supplemented with 5% (vol/vol) fetal calf serum (FCS) and 4 mM L-glutamine as described (13, 14) . Human endothelial and epithelial cells were obtained from Clonetics (San Diego). Subconfluent cultures (75-80%) (-2 x 107 cells) were used between passages 2 and 6 and cells were growth-arrested by starvation for 48 h in low-serum medium (RPMI 1640 supplemented with 0.1% FCS); the medium was replaced every 12 hr. Quiescent cells were then challenged with human recombinant PDGF-BB (10 ng/ml; GIBCO/BRL/Life Technology) and incubated further for various times up to 72 hr.
Isolation and Purification of Total Glycans. Total glycans were isolated and purified from VSMC, fibroblasts, epithelial cells, and endothelial cells at 12, 24, 48, and 72 hr after the addition of PDGF-BB. The supernatants (25 ml) were collected separately, and the cells with associated extracellular matrix (cell layer) were washed twice with 10 ml of ice-cold phosphate-buffered saline and harvested by scraping. Unstimulated cells were collected at identical time points and served as controls. Total cell number was determined in a Neubauer chamber. The total glycans were isolated and purified from the cell layers and from their respective supernatants by the same procedure. Lipids were extracted with 4 volumes of 1:2 (vol/vol) chloroform/methanol as described by Svennerholm and Fredman (15) , whose procedure also inacivates all hydrolytic enzymes. Centrifugation was carried out at 3200 x g for 20 min at 3°C and the organic solvents were removed from the resulting pellet by the addition of 10 ml of ethanol. The mixture was again centrifuged at 3200 rpm for 20 synthesis by VSMC in both the cell layer and the culture medium (Fig. 1 Upper) . In the cell layer, this increase became apparent 24 hr after the addition of PDGF and reached maximal levels (2.5-fold of control) 48 hr after stimulation, thereafter remaining constant up to 72 hr of incubation. The amount of total glycans secreted in the medium was also significantly increased in the presence of PDGF in an almost linear fashion from 24 to 72 hr of incubation. In contrast, when PDGF was added to confluent, nonproliferating VSMC cultures, there was no increase in the amount of total glycans measured in the cell layer or the culture medium (Fig. 1 Lower).
To investigate whether the effect of PDGF on total glycan synthesis by VSMC is cell-type specific, we measured the total glycan synthesis by subconfluent cultures of human fibroblasts, endothelial cells and epithelial cells 48 h after stimulation with PDGF. In this case, PDGF failed to significantly increase total glycan synthesis by these cells either in the cell layer (Fig. 2 Upper) or in the culture medium (Fig. 2 Lower) . PDGF Stimulates the Secretion ofAcidic Glycans by VSMC. The nature of the total glycans produced by VSMC in the presence or absence of PDGF was investigated by measuring their content of uronic acids and neutral hexoses. It was found that in the total glycans isolated from the cell layer, the ratio of uronic acids to neutral hexoses was not significantly altered in the presence or absence of PDGF from 12 to 72 hr of incubation (Fig. 3 Upper) . Similarly, this ratio remained constant up to 72 hr of incubation when measured in the total glycans secreted in the culture medium, in the absence of PDGF (Fig. 3 Lower) . In contrast, the ratio of uronic acids to neutral hexoses measured in the total glycans isolated from the culture medium of PDGF-stimulated VSMC increased in a linear fashion from 24 hr to 72 hr of incubation (Fig. 3 Lower).
HPLC Analysis of the Total Glycans Secreted in the Culture Medium by PDGF-Stimulated VSMC. The total glycan molecules secreted in the culture medium by VSMC 72 hr after stimulation with PDGF were further analyzed by HPLC gel filtration. The molecular mass of the ensuing glycan fractions was estimated by using chondroitin sulfates of 19.7, 28.8, 43.6, 75.8, and 101.6 kDa; heparins of 4.44, 8, and 11 kDa; and hyaluronic acid of 225 kDa as molecular weight markers. The total glycans were eluted as a major peak with Kay, the portion coefficient between the liquid phase and the gel phase, = 0.082 (Fig. 4) ; Kay = (Ve -VO)/(Vt -Vo), where Ve is the elution volume and Vt and VO are as defined in Fig. 4 . The apparent molecular mass of this glycan fraction was estimated to be 340 were continuously recorded by a Bio-Rad HPLC system. VO and Vt are the void volume and the total volume, respectively, of the gel bed. The refractive index was measured in volts.
kDa. The peak which was eluted near Vt (Kav = 0.74) corresponds to glycan species with a molecular mass of <3.5 kDa and may be attributed to small degradation products during the isolation and purification procedure.
The total glycans isolated from the culture medium of VSMC 24 hr and 48 hr after stimulation with PDGF were also analyzed by HPLC gel filtration (data not shown). The elution pattern obtained was almost identical with the elution pattern shown in Fig. 4 . However, there was an increase in the area under the curve corresponding to the 340-kDa glycan fraction from 24 hr to 72 hr. This increase coincides with the increase in the ratio of uronic acids to neutral hexoses observed from 24 hr to 72 hr, shown in Fig. 3 Lower.
Enzymological Characterization of the 340-kDa Glycan with GAG-Degrading Enzymes. To examine whether the 340-kDa glycan fraction shares common structural features to other well-characterized GAGs, enzymatic treatment with the specific GAG-degrading enzymes heparinase, heparitinase, chondroitinase ABC, keratanase, and hyaluronidase was performed. Digestion of the total glycans was initially evaluated by [3H]thymidine incorporation in VSMC after treatment with PDGF at 10 ng/ml, the 340-kDa glycan fraction, and commercially available hyaluronic acid. Results are expressed as percent of control (incubation in the presence of 0.5% FCS) and are the mean of two different experiments performed in quadruplicate. The maximal error was always <10%.
PAGE on 4-20% linear gradient gels stained with Alcian blue (data not shown) and then by HPLC gel filtration under continuous measurements of the absorbance at 206 and at 232 nm and of the refractive index. Digestion (percent) was calculated from the ratios of the area under the curve of buffer-treated substrates over the area under the curve of enzyme-treated substrates of (i) the absorbance at 206 nm, (ii) the absorbance at 232 nm, and (iii) the refractive index (Table  1 ). All GAG-degrading enzymes used could completely digest their respective specific substrates (chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, hyaluronic acid, keratan sulfate, heparan sulfate, and heparin). However, 3% of hyaluronic acid and 2% of chondroitin sulfate A could not be digested by their respective specific enzymes, which may be attributed to impurities. The 340-kDa glycan fraction could only be digested with hyaluronidase by 82%, indicating that the major part of this molecule shares a structure common to hyaluronic acid.
Functional Studies. The biological role of the 340-kDa glycan fraction was investigated by measuring the incorpora- The purified 340-kDa glycan or the standard GAGs were digested with specific GAG-degrading enzymes as described in text. The digestion was monitored by HPLC gel filtration analysis. Absorbance at 206 and 232 nm and the refractive index were continuously recorded, and their area under the curve was measured by integration analysis with the Bio-Rad HPLC, version 2.3, software system. Digestion (%) was calculated from the ratios of the area under curve of buffer-treated substrates over the area under curve of enzyme-treated substrates of: (i) the absorbance at 206 nm, (ii) the absorbance at 232 nm, and (iii) the refractive index. In all cases (i, ii, and iii) the % digestion calculated was identical. The (Fig. 5) (25) (26) (27) and has been interpreted as a direct effect of PDGF on GAG chain-elongating enzymes.
The production of this highly acidic molecule by VSMC in response to PDGF coincides in time with the observed decrease in pH of VSMC culture medium and cell growth arrest observed 48 hr after the addition of the mitogenic stimulus (unpublished results). Change of the medium and PDGF supplementation are required for further cell proliferation. These results suggest that VSMC, in response to stimulation by growth factors such as PDGF, control their proliferation by secreting in the culture medium a specific hyaluronic acid, which lowers the pH of the medium and arrests cell growth. This agrees with evidence for a role of natural components, such as heparin and heparan sulfate species, which may exist within the vessel wall and oppose the action of growth factors and hence prevent VSMC proliferation (12, 27, 28) .
The antiproliferative function of the 340-kDa hyaluronic acid molecule secreted by VSMC in response to PDGF also agrees with the known biological role of hyaluronic acid that is associated with cell migration. The secretion of this molecule by proliferating VSMC after stimulation by PDGF could reflect an autoregulatory mechanism by which VSMC control the mitogenic effect of PDGF. Since the development of atherosclerotic lesions involves the transition of VSMC from a quiescent to a proliferating phenotype, the 340-kDa glycan fraction may play a functional role in the pathophysiology of atherosclerosis. During the development of the atherosclerotic lesions, damage of the endothelium enhances the appearance of platelets and macrophages at the site of injury and the release of high concentrations of growth factors by these cells. It is possible that VSMC may try to counteract these pathologic alterations and mobilize antiproliferative mechanisms, by augmenting the synthesis and release of specific molecules, such as the above described 340-kDa hyaluronic acid species. Ultimately, VSMC migration to the luminal surface of the blood vessel wall and the ensuing proliferative response would be trations of mitogenic factors, such as PDGF, and the increased levels of free hyaluronic acid. Thus, this specific form of hyaluronic acid may be positioned to act as a negative control element during the regulation of cell proliferation and as a positive control element during the regulation of cell migration. We have recently reported that PDGF induces proliferation of nontransformed mesenchymal cells by inducing the expression of the interleukin 6 (IL-6) gene (29) . When one considers the negatively regulating potency of hyaluronic acid on PDGF-dependent proliferation, events subsequent to the induction of the IL-6 gene and that of other interleukins involved in inflammation and wound-healing may also be controlled by hyaluronic acid-rich GAGs. E.P. was supported by a fellowship from the European Commission (BMH1-CT-94-5004).
